PlainPharmaWatch

CMS Open Payments · Tool

Omniscient Neurotechnology America Ltd vs Merete Technologies, Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Omniscient Neurotechnology America Ltd has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 3,397, versus 3,135 for the other company. Its single largest recorded recipient represents 45.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Omniscient Neurotechnology America Ltd
HHI 3,397 · top recipient 45.2%
Ranked #518 of 1,838 companies by HHI
Merete Technologies, Inc
HHI 3,135 · top recipient 46.3%
Ranked #552 of 1,838 companies by HHI

Payment Overview

Total Payments
$73.2K
% of Industry
0.0%
Transactions
72
Avg per Transaction
$1.0K
Recipients
72
Avg per Recipient
$1.0K
Payment Types
3
Top Payment Type
Consulting Fee
Total Payments
$72.1K
% of Industry
0.0%
Transactions
29
Avg per Transaction
$2.5K
Recipients
29
Avg per Recipient
$2.5K
Payment Types
2
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Omniscient Neurotechnology America Ltd vs Merete Technologies, Inc - total reported payments in CMS Open Payments PY2024

Omniscient Neurotechnology…$73.2KMerete Technologies, Inc$72.1K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Omniscient Neurotechnology America Ltd

Consulting Fee $60.1K

82.2%

Travel and Lodging $8.3K

11.4%

Food and Beverage $4.7K

6.4%

Merete Technologies, Inc

Royalty or License $44.6K

61.9%

Consulting Fee $27.5K

38.1%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Omniscient Neurotechnology America Ltd

  1. 1

    RANDY Scott D'AMICO M.D.

    $33,093.46 · 27 txns

  2. 2

    MICHAEL IVAN M.D.

    $22,580.35 · 11 txns

  3. 3

    SIMON HANFT M.D.

    $14,598.40 · 12 txns

  4. 4

    JONATHAN SHERMAN

    $515.05 · 4 txns

  5. 5

    ZACHARY HICKMAN

    $381.88 · 3 txns

Merete Technologies, Inc

  1. 1

    Joseph Benevenia

    $33,413.02 · 4 txns

  2. 2

    William Bush

    $21,371.97 · 9 txns

  3. 3

    Thomas Nordquist

    $4,000.00 · 2 txns

  4. 4

    Douglas Pacaccio

    $3,996.72 · 4 txns

  5. 5

    Steven Neufeld

    $3,312.56 · 4 txns

Summary Comparison

Metric Omniscient Neurotechnology America Ltd Merete Technologies, Inc
Total Payments $73.2K $72.1K
% of Industry Total 0.0% 0.0%
Transaction Count 72 29
Avg per Transaction $1.0K $2.5K
Recipient Count 72 29
Avg per Recipient $1.0K $2.5K
Payment Type Count 3 2
Top Payment Type Consulting Fee Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.